Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion type Assertion NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_head.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion description "[Moreover, only in the highest CETP quartile, pravastatin significantly reduced the MSD- (P=0.003) and MOD-decrease (P=0.014) compared with placebo, and, notably, this was independent of baseline lipids and differential lipid changes in these quartiles.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_provenance.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion evidence source_evidence_literature NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_provenance.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion SIO_000772 14984434 NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_provenance.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion wasDerivedFrom befree-2016 NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_provenance.
- NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_assertion wasGeneratedBy ECO_0000203 NP432984.RAdZmk94o_8tdlD2aURfzmDlS0VJrZane3HBCfKEf4yPk130_provenance.